Solutions

Online Inquiry

* Your Name

Phone Number

* E-mail Address

* Services Interested

Project Description

* Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Inflammatory Diseases

Inflammatory diseases cover a wide range of conditions that are associated with chronic ongoing inflammation that can affect different tissues and organs. While inflammation serves as a protective mechanism in the body, its uncontrolled form can be extremely damaging and destructive, leading to ongoing tissue injury and function. Protheragen is actively engaged in developing innovative therapies and compounds that target the MyD88 pathway, aiming to address the critical unmet needs in the research and development of treatments for inflammatory diseases.

Introduction to Inflammatory Diseases

Inflammatory diseases form a unique group of chronic disorders differentiated by an excess inflammatory reaction in humans. The condition tends to cause inflammation that leads to destruction of tissue and organs, which in turn renders the subject to a number of life-altering symptoms. The phenomenon is in most cases attributed to a wide range of genetic susceptibility, external stimuli, and abnormal immunity.

MyD88 in Inflammatory Pathogenesis

Inflammatory diseases' pathogenesis entails the modulating of the different immune system cells and pathways which increase and maintain inflammation for some chronic conditions. In this system, MyD88, which is Myeloid Differentiation Primary Response 88 is very important for the disease processes for it functions pathologically in the illness. MyD88 is an important adaptor protein for it is critical in the signal transduction processes of the vast majority of Toll-like receptors and interleukin-1 receptor family.

Fig.1 The protective effect of quercetin on macrophage pyroptosis via TLR2/Myd88/NF-κB and ROS/AMPK pathway. Luo et al., 2022)

MyD88 acts as a fuel of inflammation in the body and in a number of chronic diseases it is believed that these portions of the immune system may mediate the pathological changes. In other words, the abnormal TLR/IL-1R pathway activation through MyD88 Hypersensitivity is thought to be critical in the development and pathophysiology of inflammation and related tissue injury. MyD88 is critical in signal transduction of the TLR, it is believed that excessive activation of MyD88 can result in production of pro-inflammatory mediators like TNF-α, IL-1β and IL-6 in chronic inflammation seen in hepatitis and neuroinflammatory conditions. Such an approach to modulate MyD88 is believed to targeted approach to reduce pathological inflammation and inflammation induced cellular damage.

Targeting MyD88 for the Therapeutic Development in Inflammatory Diseases

Drug Name	Mechanism of Action	Indication	Key Progress	Development Stage
TJ-M2010-5	Small molecule allosteric modulator blocking TIR domain dimerization	COPD/Sepsis	COPD patients show reduced IL-6/TNF-α; Sepsis models demonstrate improved survival	Phase I
c(MyD 4-4)	Cyclic peptide inhibitor suppressing MyD88 homodimerization	Viral pneumonia	SARS-CoV-2 models show reduced viral load and attenuated lung injury	Preclinical
ST2825	BB-loop mimetic peptide disrupting TIR interactions	Acute lung injury	LPS-induced ARDS models show reduced neutrophil infiltration	Preclinical

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

For autoimmune diseases and MyD88-targeted novel compound and therapy development, Protheragen provides complete, integrated solutions. With appropriate project requirements, our dedicated expert teams employ advanced technologies for accelerated discovery and preclinical development, including tailored therapeutic discovery and disease model development services.

MyD88-Targeted Inflammatory Diseases

Protheragen leads the innovation and development of MyD88-targeted and tailored compounds for a diverse range of inflammatory diseases and disorders. We enable Protheragen to create tailored compounds that accelerate the discovery and MyD88-driven application of novel and efficacious therapies through a detailed understanding of each condition's inflammatory profile for:

Therapeutic Discovery Platform for Inflammatory Diseases

Protheragen's therapeutic candidate development services provide robust, comprehensive support across the entire spectrum of drug discovery and preclinical advancement, with a dedicated focus on MyD88-related targets.

Disease Models Development for Inflammatory Diseases

Protheragen delivers a comprehensive toolkit of advanced disease model development services to accurately evaluate the efficacy and safety of MyD88-targeted therapeutic candidates.

Animal Models Development

Protheragen specializes in providing one-stop preclinical development services dedicated to advancing MyD88-targeted therapeutics for inflammatory diseases. Our end-to-end solutions streamline the drug development process, from disease model development to in-depth pharmacokinetics and drug safety evaluation. Other focuses include investigator-initiated trials aimed at expediting the primary assessment stage.

If you are interested in our services, please don't hesitate to contact us.

References

Luo, X., et al. "The Protective Effect of Quercetin on Macrophage Pyroptosis Via Tlr2/Myd88/Nf-Kappab and Ros/Ampk Pathway." Life Sci 291 (2022): 120064.
Wang, X., et al. "Interleukin-18 and Il-18bp in Inflammatory Dermatological Diseases." Front Immunol 14 (2023): 955369.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.